Stoke Therapeutics (STOK) EBT Margin (2022 - 2025)
Historic EBT Margin for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to 372.7%.
- Stoke Therapeutics' EBT Margin rose 1673500.0% to 372.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.63%, marking a year-over-year increase of 6497300.0%. This contributed to the annual value of 242.74% for FY2024, which is 9516200.0% up from last year.
- As of Q3 2025, Stoke Therapeutics' EBT Margin stood at 372.7%, which was up 1673500.0% from 169.96% recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' EBT Margin registered a high of 71.99% during Q1 2025, and its lowest value of 1237.2% during Q2 2023.
- Over the past 4 years, Stoke Therapeutics' median EBT Margin value was 625.57% (recorded in 2024), while the average stood at 591.44%.
- Per our database at Business Quant, Stoke Therapeutics' EBT Margin tumbled by -4729200bps in 2023 and then soared by 9163200bps in 2024.
- Stoke Therapeutics' EBT Margin (Quarter) stood at 786.32% in 2022, then dropped by -23bps to 963.56% in 2023, then skyrocketed by 95bps to 47.24% in 2024, then crashed by -689bps to 372.7% in 2025.
- Its EBT Margin stands at 372.7% for Q3 2025, versus 169.96% for Q2 2025 and 71.99% for Q1 2025.